Istituti Clinici Scientifici Maugeri IRCCS, Rheumatology Unit, Institute of Castel Goffredo, Mantua, Italy.
Hand surgery Dpt, ULSS Serenissima, Venice, Italy.
Clin Ter. 2023 May-Jun;174(3):245-248. doi: 10.7417/CT.2023.2528.
Osteoarthritis (OA) is a common disease in the elderly people, inducing pain and functional limitations. Clodronate (CLO) a first generation non-nitrogen containing bisphosphonate has been purposed as a treatment of OA, being effective on pain, inflammation, bone marrow oedema, osteophytosis and cartilage regeneration. Intra-muscular routes of CLO showed efficacy in the treatment of Knee OA (KOA) and erosive OA of the hand. In KOA intraarticular CLO at low doses (0.5-2 mg) showed efficacy as well as hyaluronic acid (HA), being able to improve the effectiveness if associated to HA.
Nine Consecutive patients (4 female, 5 male, mean age 78,22) with KOA at 2nd or 3rd degree following Kellgren-Lawrance scale, non responder to HA and unintended to surgery. They were treated with intraarticular CLO at the weekly dose of 20 mg, plus lidocaine 1% in 5 cc of saline solution for a route of 5 weekly infil-trations, followed by a second route of 5 intraarticular infiltrations 3 months after the first course. Visual analog score (VAS) pain and Tegner-Lysholm Score (TLS) were used to assess changes following CLO treatment.
Baseline pain was 6,77/10, reduced to 1,09 at day 150 (after second course) and to 2,3/10 at day 240. TLS at baseline was 56,7/100, improved to 96,7 at day 150 and to 84,1 at day 240. At day 240 only 2 out of 9 patients had a negative judgement of the treatment and decided to stop it, while 7 were satisfied and available to a further course. There was no increase of consumption of anti-inflammatory or analgesic drugs. A short time lasting pain after the injections was registered in all patients.
In a small cohort of patients affected by KOA, non responders to intraarticular HA a higher dose of intraarticular CLO in KOA showed good compliance, amelioration of pain and functionality.
骨关节炎(OA)是老年人常见的疾病,会引起疼痛和功能受限。氯膦酸(CLO)是第一代非氮双膦酸盐,已被提议作为 OA 的治疗方法,对疼痛、炎症、骨髓水肿、骨赘形成和软骨再生有效。CLO 的肌肉内途径对膝骨关节炎(KOA)和手部侵蚀性 OA 有效。在 KOA 中,低剂量(0.5-2mg)关节内 CLO 与透明质酸(HA)一样有效,如果与 HA 联合使用,能够提高疗效。
9 名连续患者(4 名女性,5 名男性,平均年龄 78.22 岁),根据 Kellgren-Lawrance 量表,处于 2 或 3 级 KOA,对 HA 无反应,且不打算手术。他们接受每周 20mg 的关节内 CLO 治疗,加 1%利多卡因 5cc 生理盐水,每周 5 次注射,第一疗程后 3 个月进行第二疗程 5 次关节内注射。视觉模拟评分(VAS)疼痛和 Tegner-Lysholm 评分(TLS)用于评估 CLO 治疗后的变化。
基线疼痛为 6.77/10,第 150 天(第二疗程后)降至 1.09,第 240 天降至 2.3/10。基线 TLS 为 56.7/100,第 150 天改善至 96.7,第 240 天改善至 84.1。第 240 天,9 名患者中有 2 名对治疗结果不满意并决定停止治疗,而 7 名患者满意并愿意接受进一步治疗。抗炎或镇痛药的消耗量没有增加。所有患者在注射后都出现短暂的疼痛。
在一组对关节内 HA 无反应的 KOA 患者中,关节内给予较高剂量的 CLO 治疗 KOA 具有良好的顺应性,可改善疼痛和功能。